SUSTAIN 340B Act Overhauls Drug Discount Rules: New Audits, Tighter Patient Definitions, and User Fees Set for 2031.

The SUSTAIN 340B Act is a massive tune-up for a decades-old program that helps safety-net hospitals and clinics buy drugs at a discount. At its core, the bill tries to fix the growing friction between drug makers, pharmacies, and hospitals by creating a stricter rulebook. It sets a formal definition for who counts as a 'patient'—requiring a documented relationship within the last two years—and establishes a new 'data clearinghouse' to make sure discounts aren't being double-counted when Medicaid or private insurance is involved. While it aims to keep the program honest, it also introduces a new user fee for participating hospitals starting in 2031 to pay for all this new oversight.

The Fine Print on Pharmacies and Referrals

For most of us, picking up a prescription at a local CVS or Walgreens is routine, but for these safety-net providers, using 'contract pharmacies' has become a legal minefield. The bill requires these hospitals to register every single pharmacy they work with and cancels contracts that haven't been used in a year. It also creates a new pathway for 'referral prescriptions.' If your community clinic refers you to a specialist who isn't part of their building, the clinic can still give you the 340B discounted price, provided they keep meticulous records of the referral and the follow-up care. This is a win for patients who need specialized care but could be a headache for clinics that now have to track every outside consultation for three years to pass an audit.

Accountability or Administrative Overload?

Transparency is the big buzzword here. Hospitals will now have to publicly report exactly how they spend the money they save from these drug discounts, including how much 'charity care' they actually provide to the uninsured (Section 7). For the workers running these clinics, this means a lot more paperwork and a higher risk of being audited by both the government and drug manufacturers. If an audit finds a clinic is playing fast and loose with the rules, they could be kicked out of the program for three years. It’s a classic 'straighten up or ship out' approach that aims to ensure the savings actually reach low-income patients rather than just padding a hospital's bottom line.

Protecting the Pipeline

One of the most direct impacts for patients is a new 'nondiscrimination' clause (Section 11). It stops insurance companies and Pharmacy Benefit Managers (PBMs) from paying 340B pharmacies less just because they are part of the discount program. Think of it as a 'fair play' rule: insurers can't charge you more or treat your pharmacy differently just because the drug was bought at a discount. However, the bill also puts the brakes on expansion by making newly acquired 'child sites' (like a new clinic branch) wait three years before they can start using 340B discounts. This might slow down how quickly a hospital can bring cheaper meds to a new neighborhood, even as it tries to prevent the program from growing too fast for the government to track.